Loading…

miR-638 promotes melanoma metastasis and protects melanoma cells from apoptosis and autophagy

The present study identified miR-638 as one of the most significantly overexpressed miRNAs in metastatic lesions of melanomas compared with primary melanomas. miR-638 enhanced the tumorigenic properties of melanoma cells in vitro and lung colonization in vivo. mRNA expression profiling identified ne...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2015-02, Vol.6 (5), p.2966-2980
Main Authors: Bhattacharya, Animesh, Schmitz, Ulf, Raatz, Yvonne, Schönherr, Madeleine, Kottek, Tina, Schauer, Marianne, Franz, Sandra, Saalbach, Anja, Anderegg, Ulf, Wolkenhauer, Olaf, Schadendorf, Dirk, Simon, Jan C, Magin, Thomas, Vera, Julio, Kunz, Manfred
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The present study identified miR-638 as one of the most significantly overexpressed miRNAs in metastatic lesions of melanomas compared with primary melanomas. miR-638 enhanced the tumorigenic properties of melanoma cells in vitro and lung colonization in vivo. mRNA expression profiling identified new candidate genes including TP53INP2 as miR-638 targets, the majority of which are involved in p53 signalling. Overexpression of TP53INP2 severely attenuated proliferative and invasive capacity of melanoma cells which was reversed by miR-638. Depletion of miR-638 stimulated expression of p53 and p53 downstream target genes and induced apoptosis and autophagy. miR-638 promoter analysis identified the miR-638 target transcription factor associated protein 2α (TFAP2A/AP-2α) as a direct negative regulator of miR-638, suggestive for a double-negative regulatory feedback loop. Taken together, miR-638 supports melanoma progression and suppresses p53-mediated apoptosis pathways, autophagy and expression of the transcriptional repressor TFAP2A/AP-2α.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.3070